Drug-drug interactions with systemic antifungals in clinical practice

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 11, 2007, Pages 1227-1233

  Depont, Fanny ^a,b   Vargas, Frédéric ^c   Dutronc, Hervé ^d   Giauque, Emmanuelle ^b   Ragnaud, Jean Marie ^b,d   Galpérine, Tatiana ^d   Abouelfath, Abdelilah ^a,b   Valentino, Ruddy ^b,c   Dupon, Michel ^b,d   Hébert, Guillaume ^b   Moore, Nicholas ^a,b,c  

^a INSERM U657   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

Author keywords

Amphotericin B; Antifungal agents; Drug drug interaction; Fluconazole; Flucytosine; Intensive care; Invasive fungal infection; Itraconazole; Outcomes research

Indexed keywords

AMIKACIN; AMIODARONE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BUMETANIDE; CYCLOSPORIN; DESLANOSIDE; ERYTHROMYCIN; FLUCONAZOLE; FLUCYTOSINE; FUROSEMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROCORTISONE; ISEPAMICIN; ITRACONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; MIDAZOLAM; NETILMICIN; PREDNISOLONE; RIFAMPICIN; ZIDOVUDINE;

ADULT; AGED; ARTICLE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FEVER; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; INTENSIVE CARE UNIT; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEOPLASM; NEPHROTOXICITY; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT;

EID: 36248953162     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1473     Document Type: Article

References (17)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5: 55-68.
2. Wu JJ, Pang KR, Huang DB, et al. Therapy of systemic fungal infections. Dermatol Ther 2004; 17: 532-538.
3. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18: 83-97.
4. Deray G, Mercadal L, Bagnis C. Nephrotoxicity of amphotericin B. Nephrologie 2002; 23: 119-122.
5. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-180.
6. Chafin CC, Self TH. Clinically significant drug interactions with the azole antifungals. J Crit Illn 1999; 14: 625-626.
7. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141 (Suppl 56): 26-32.
8. Yu DT, Peterson JF, Seger DL, et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 2005; 14: 755-767.
9. Isoherranen N, Kunze KL, Allen KE, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32: 1121-1131.
10. Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemothe 2002; 46: 160-165.
11. Pichard L, Fabre I, Fable G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
12. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-1407.
13. Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphoteticin B therapy. Am J Med 2001; 111: 528-534.
14. Krcmery V, Jr., Fuchsberger P, Gocar M, et al. Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients. Chemotherapy 1991; 37: 287-291.
15. Hogan WJ, Storb R. Use of cyclosporine in hematopoietic cell transplantation. Transplant Proc 2004; 36: 367S-371S.
16. Florea NR, Capitano B, Nightingale CH, et al. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003; 35: 2873-2877.
17. Marchetti O, Moreillon P, Glauser MP, et al. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 2000; 44: 2373-2381.